Completion of human studies

28 July 2015

OptiBiotix Health plc

 ("OptiBiotix" or the Company")

Completion of Human Studies

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of clinical studies on its capsular food supplement to reduce cholesterol.

OptiBiotix announced in December 2014 that it had contracted the University of Reading to undertake human studies on 50 subjects who have raised cholesterol and its associated increased risk of cardiovascular disease ("CVD"). The aim of the study was to establish the extent of the cholesterol lowering potential of its product in this group of volunteers.

The study commenced at the start of January with the 50 volunteers separated into three groups containing 10, 20, and 20 volunteers respectively. All groups have now completed treatment with no compliance or safety concerns raised. The study has completed on schedule allowing sample testing and data analysis to take place with reporting in September 2015 as planned.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased that we are able to announce the completion of clinical studies on our capsular food supplement with no safety or compliance concerns raised. Volunteer samples will now be tested and the results subjected to statistical analysis to determine the potential of our cholesterol lowering product. High cholesterol levels are an established risk factor for CVD which the World Health Organisation predicts will be a contributory factor in up to 40% of all human deaths by 2020. We hope that these studies will make a significant contribution to improving people's lives and build a valuable and sustainable business for shareholders."

About OptiBiotix Health PLC - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.